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The diagnostic accuracy of percutaneous transhepatic cholangioscopy (PTCS) was
compared to that of three radiologic modalities in distal common bile duct (CBD)
strictures for the evaluation of clinical application. Ninety-five patients who under-
went PTCS for the evaluation of distal CBD strictures (35 malignant and 60 benign)
whose masses were not obvious from radiologic imagings were included. Confirma-
tive diagnosis could not be reached by endoscopic retrograde cholangiopancre-
atography (ERCP) or radiologic findings in all cases. Specific findings on the com-
puted tomography (CT), magnetic resonance cholangiopancreatography (MRCP)
and direct cholangiography were analyzed among 68 (25 malignant and 43 benign)
out of the 95 patients in order to determine the sensitivity and specificity of three
radiologic studies for the diagnosis of malignant distal CBD strictures, and to com-
pare those results with those by a combination of PTCS-guided biopsy and tumor
vessel observation on cholangioscopy. The sensitivity/specificity of CT, MRCP and
direct cholangiography including ERCP in diagnosing malignant distal CBD stric-
tures were 42.9%/65.8%, 53.3%/58.3%, and 70.8%/47.6% respectively, while it was
96%/100% for the combination of PTCS-guided biopsy and tumor vessel. PTCS is
a useful method for differential diagnosis of distal CBD strictures, particularly when
it is difficult to distinguish benign from malignant strictures by radiologic studies and
when peroral approach is not feasible.
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INTRODUCTION
Various inflammatory diseases and benign or malignant
tumors are known to cause distal common bile duct (CBD)
strictures (1-3). It is important to determine whether a bil-
iary stricture has a benign or malignant cause as each requires
a different treatment approach. Furthermore, as a normal dis-
tal CBD may show a narrow distal segment, it is difficult to
assess the clinical significance of a distal CBD narrowing.
Generally, endoscopic retrograde cholangiopancreatogra-
phy (ERCP) has been considered the method of choice for
diagnosing biliary strictures due to its accuracy in establish-
ing the site and cholangiographic features of strictures (4).
However, there are some conditions that ERCP could not
be successfully completed such as previous stomach surgery. In
addition, other diagnostic approaches are required to evaluate
the biliary stricture when tissue sampling is difficult using
ERCP.
Percutaneous transhepatic cholangioscopy (PTCS) might
be useful for the diagnosis and treatment of biliary strictures
(5, 6). However, there are no published studies examining
the usefulness of PTCS for evaluating distal CBD strictures. 
The usefulness of PTCS for differential diagnosis of distal
CBD strictures was evaluated in the present study. In addi-
tion, PTCS, computed tomography (CT), magnetic resonance
cholangio pancreatography (MRCP) and direct cholangiog-
raphy including ERCP were compared in terms of their accu-
racy in diagnosing distal CBD strictures.
MATERIALS AND METHODS
Between January 1995 and December 2004, 95 consecu-
tive patients who underwent PTCS for the evaluation of dis-
tal CBD strictures at Asan Medical Center, Seoul, Korea,
were enrolled in this study. The medical records and radio-
logic findings were reviewed and clinical information was
collected retrospectively. Distal CBD stricture was diagnosed
by endoscopic retrograde cholangiography or cholangiograms
obtained by means of percutaneous transhepatic biliary dra-
inage (PTBD) tubes, and radiologic finding including CT
or MRCP. 
If the malignant distal CBD stricture was obvious, these
patients promptly sent for operation. However, patients whose
other masses were unable to be seen through radiologic find-
ings and the cases of which the nature of distal CBD stric-ture was inconclusive as to benign or malignant underwent
PTCS. 
Cases in which malignancy could not be proven by tissue
biopsy results were excluded from the malignant group, even
if their strictures were clinically suspicious for malignancy.
Those patients with distal CBD stricture, which was diag-
nosed by postoperative cholangioscopy via T-tube tract, were
also excluded.
Malignant distal CBD strictures were confirmed when
malignant cells were observed in specimens obtained using
PTCS-guided biopsy or surgery. The malignant distal CBD
stricture group comprised of 35 patients (22 men and 13
women; mean age, 66 yr) and the diagnosis of malignancy
was confirmed by surgical resection with or without PTCS-
guided biopsy in 29 and only PTCS-guided biopsy in 6. Stric-
tures were considered benign when malignant cells were not
found in resected specimens from the patients who under-
went surgery or when there was no clinical and radiology
evidence of disease progression during more than 6 months
of follow-up in patients with negative PTCS-biopsy find-
ings who did not undergo surgery. The benign distal CBD
stricture group comprised of 60 patients (45 men and 15
women; mean age, 61 yr) and the median follow-up period
for the benign group was 26 months (up to 60 months).
In our study, 59 out of 95 patients could not undergo suc-
cessful ERCP due to a previous history of Roux-en-Y esopha-
gojejunostomy or gastrojejunostomy (n=31), cannulation
failure (n=19), cardiovascular disease (n=4), difficulty to
assume a lateral position (n=2) and others (n=3). Six patients
underwent PTCS instead of ERCP, because ERCP had been
performed at another hospital for evaluation of indetermi-
nate distal CBD stricture suspicious for malignancy and they
were referred to our tertiary referral center for cholangioscopy.
Thirty patients underwent ERCP and in 8 out of 30 patients,
we could not get the ERCP-guided biopsy and brush cytol-
ogy due to tight distal CBD structures (n=5), hemobilia
(n=1) and others (n=2). In 8 patients, ERCP-guided tissue
sampling of distal CBD stricture was not done and we could
not find the cause. The other 14 patients were unsuccessful-
ly diagnosed because no additional information was obtained
even though an ERCP-guided biopsy and a brush cytology
were done. Consequently confirmative diagnosis could not
be reached by ERCP alone in all cases. 
PTCS was performed as inpatients procedures. PTBD was
performed using a 8.5-Fr pigtail catheter under fluoroscopic
guide. Two or three days after the PTBD, the percutaneous
tract was dilated for the passage of the cholangioscope usu-
ally by one-stage dilation (eg, from 8.5 F to 16 or 18 F). For
the sinus tract maturation, 7-10 days were required for the
diagnostic cholangioscopy. PTCS was performed using a 5.2
mm outer diameter cholangioscope (CHF P20Q: Olympus
Optical Ltd, Tokyo, Japan) or 4.9 mm outer diameter cholan-
gioscope (FCN-15X; Pentax, Tokyo, Japan) with medica-
tion of meperidine (25-50 mg) and/or midazolam (3-5 mg).
PTCS was performed by 3 endoscopists who had PTCS expe-
rience of at least 40 cases yearly for 2-7 yr. The distal CBD
strictures were carefully examined for the presence of abnor-
mal dilated vessel and mucosal abnormality. Targeted biop-
sies were performed with a 1.8 mm diameter forceps (FB-
19SX01, Olympus) under direct vision.
Laboratory data such as CA 19-9 and carcinoembryonic
antigen (CEA) concentrations were compared, and CT, MRCP,
direct cholangiography findings and PTCS findings were
analyzed. Direct cholangiography was defined as endoscopic
retrograde cholangiography or cholangiograms obtained by
means of PTBD tubes. Percutaneous transhepatic cholan-
giogram data was analyzed when ERCP was unsuccessful. 
Mucosal findings such as tumor vessel, mucosal irregularity
and mucosal color change were compared on cholangioscopy.
A tumor vessel was defined as an abnormally proliferating
and tortuous vascular structure in the bile duct stricture
mucosa. Mucosal irregularity was defined as granular mucosa,
nodular mucosa, papillary mucosa, mucosal hyperplasia and
irregular mucosa. Mucosal color change was defined as whitish
or hyperemic mucosa. PTCS-guided biopsies were perform-
ed at the sites of stricture, tumor vessel, mucosal irregulari-
ty and mucosal color change and three more biopsy speci-
mens per patient were obtained. The sensitivity and speci-
ficity of PTCS-guided biopsy were calculated for the diag-
nosis of malignant versus benign distal CBD stricture. Addi-
tionally the sensitivity and specificity of combination of PTCS-
guided biopsy and tumor vessel on cholangioscopy were com-
pared with those by CT, MRCP and direct cholangiography
for diagnosis of malignant distal CBD stricture. 
The radiologist reviewed all radiologic images retrospec-
tively by using a picture archiving and communication sys-
tem (PACS) workstation monitor. The reviewer had no knowl-
edge of clinical data or whether distal CBD strictures were
diagnosed as malignant or benign following surgery or biopsy.
The proportion of patients who underwent all three types of
imaging study (CT, MRCP and direct cholangiography) was
relatively small, thus the analysis included patients that under-
went two or more imaging studies, which comprised 68 of
the 95 patients (25 malignant, 43 benign). Twenty-seven
patients were excluded from this analysis either because there
were no images before decompression, the images were older
than the obligatory storage period expiry date (5 yr) or the
quality of outside images was very poor.
A stricture was assumed to be malignant if characterized
by wall thickening, enhancement and abrupt narrowing
according to the CT, and an irregular margin, asymmetric
and abrupt narrowing according to MRCP and direct cholan-
giography. The sensitivity and specificity of diagnosis using
CT, MRCP and direct cholangiography for malignant distal
CBD strictures were determined.  
All procedures were explained to patients, and all patients
gave informed written consent to the procedures. The study
was approved by the Institutional Review Board of Asan
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Statistical analysis
All statistical analyses were performed using the SPSS 12.0
statistical software program (SPSS, Inc., Chicago, IL, U.S.A.).
Potential predictive factors for PTCS findings that could be
diagnosed as a malignant distal CBD stricture were analyzed
with chi-square tests for univariate comparisons. Factors that
were deemed of potential importance on univariate analysis
(p<0.05) were included in the multivariate analysis. Logis-
tic regression was used for multivariate analysis of these fac-
tors. Student’s t-test was used to test for the differences bet-
ween the benign and malignant groups in terms of labora-
tory test results, stricture length and upstream ductal diam-
eters according to the CT. Chi-square tests were used to com-
pare the radiograpic findings according to MRCP and direct
cholangiography. A p value of <0.05 was considered to indi-
cate a significant difference. 
RESULTS
Baseline clinical findings are summarized in Table 1. The
mean serum values for alkaline phosphatase (ALP), gamma
glutamyl transpeptidase (GGT) and total bilirubin were
higher in the malignant than those in the benign group (p<
0.05). The mean CA 19-9 levels of the benign and malig-
nant groups were 227 μ /mL and 396 μ /mL, respectively, with-
out a significant difference between the two groups (Table 2). 
The PTCS findings for the malignant and benign groups
were compared. PTCS showed tumor vessels in 26, mucosal
irregularity in 21 and mucosal color change in 12 of 35 malig-
nant distal CBD stricture patients, while tumor vessels were
not observed in benign groups and mucosal irregularity and
mucosal color change were seen in 21 and 8 of 60 benign
stricture patients. On univariate analysis, malignant distal
CBD stricture was associated with tumor vessel, mucosal
irregularity and mucosal color change (p<0.05). However,
multivariate stepwise logistic regression analysis showed
that the tumor vessel was only an independently differenti-
ating variable (p<0.05) (Table 3). 
In 35 patients of the malignant group, 33 underwent a
PTCS-guided biopsy. For the remaining 2 patients, while
biopsies were attempted up to four times, adequate biopsy
specimens could not be obtained, and the malignancy was
confirmed following surgical resection. Of the 3 patients of
malignant group, PTCS-guided biopsy diagnosed their stric-
tures as chronic inflammation. Therefore, five patients could
not be diagnosed by PTCS-guided biopsy. Sixty patients of
benign group underwent PTCS-guided biopsy and they were
diagnosed with benign distal CBD stricture. Those patients
with benign distal CBD strictures showed no significant inter-
val change during the at least 6 months follow-up period. 
The diagnostic accuracies associated with PTCS-guided
biopsy and tumor vessel are shown in Table 4. The most valu-
able cholangioscopic finding for indicating the presence of a
malignant distal CBD stricture was found to be the tumor
vessel. Furthemore, a combination of tumor vessel findings
and PTCS-guided biopsy resulted in a superior preoperative
diagnosis compared to tumor vessel or PTCS-guided biopsy
alone, which provided 97.1% sensitivity, 100% specificity,
100% positive predictive value and 98.4% negative predic-
tive value (Table 4). 
The sensitivity and specificity of combined PTCS-guided
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Malignant group 
(n=35)
Benign group
(n=60)
Age (yr) 66±9.8 61±10.5
Gender (M:F) 22:13 45:15
Clinical manifestation
Jaundice 26 10
Abdominal pain 5 26
Fever 3 7
Imaging abnormality* 1 16
Previous operation history
Biliary tract surgery 3 28
Stomach surgery 10 22
None 23 18
Table 1. Baseline characteristic in the malignant and benign
groups
*, Distal common bile duct stricture was found by radiologic imaging
on health inspection.  PTCS, percutaneous transhepatic cholangioscopy.
AST, aspartate transaminase; ALT, alkaline transaminase; GGT, gamma
glutamyl transpeptidase; CEA, carcinoembryonic antigen.
Malignant group 
(n=35)
Benign group
(n=60)
p
value
Albumin (g/dL) 3.2±0.65 3.6±0.54 0.002
AST (IU/L) 169±256.6 104±187.5 0.160
ALT (IU/L) 151±146.2 96±120.2 0.053
Alkaline phosphatase (IU/L) 828±692.8 329±347.2 0.001
GGT (IU/L) 497±450.4 234±247.6 0.007
Total bilirubin (mg/dL) 11.2±7.66 3.2±5.79 <0.001
CA 19-9 (μ /mL) 396±735.0 227±977.8 0.421
CEA (ng/mL) 4.1±2.83 2.5±1.02 0.011
Table 2. Initial laboratory results in malignant and benign groups
Malignant 
group 
(n=35)
PTCS finding
Benign
group 
(n=60)
Univariate
(p)
Multivariate
(p)
Tumor vessel 26 0 <0.001 <0.001
Mucosal irregularity 21 21 0.018 0.167
Mucosal color change 12 8 0.016 0.420
Table 3. PTCS findings regarding distal common bile duct stric-
tures in malignant and benign groupsbiopsy plus tumor vessel were compared with those of CT,
MRCP and direct cholangiography for the diagnosis of malig-
nant distal CBD strictures (Table 5). Sixty-eight patients
were included in this analysis. The sensitivity/specificity of
CT, MRCP and direct cholangiography were 42.9%/65.8%,
53.3%/58.3% and 70.8%/47.6%, respectively, while it was
96%/100% for the combined assessment using tumor vessel
and PTCS-guided biopsy findings. Among 68 patients, 23
patients were suspected of malignancy according to at least
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Fig. 1. Studies of a 59-yr-old male patient. While radiologic findings
suggested a malignant distal common bile duct stricture, PTCS
and biopsy findings revealed a benign stricture. (A) MRCP image
showing abrupt and asymmetric narrowings. (B) ERCP image show-
ing abrupt and asymmetric narrowings. (C) PTCS image showing
no tumor vessel or mucosal abnormality. 
A
C
B
Biopsy Tumor vessel 
Tumor vessel
or biopsy
Sensitivity 85.7% (30/35) 74.3% (26/35) 97.1% (34/35)
Specificity 100% (60/60) 100% (60/60) 100% (60/60)
Positive predictive value 100% 100% 100%
Negative predictive value 94.60% 87% 98.40%
Table 4. Diagnostic accuracy of PTCS-guided biopsy, tumor
vessel and combination of PTCS-guided biopsy and tumor ves-
sel observation 
CT 
(n=59)
MRCP
(n=39)
Direct cholan-
giography
(n=66)
Tumor vessel
or biopsy
(n=68)
Sensitivity 42.9% 53.3% 70.8% 96%
Specificity 65.8% 58.3% 47.6% 100%
Table 5. Diagnostic accuracy of CT, MRCP, direct cholangiog-
raphy and combined tumor vessel plus PTCS-guided biopsy
findingsone of CT, MRCP or direct cholangiographic images, and
also shown to have malignant distal CBD strictures accord-
ing to PTCS findings and biopsies. Sixteen patients showed
benign radiologic features in distal CBD strictures and also
showed benign PTCS findings and biopsy results. For 27
patients, while radiologic images indicated malignant distal
CBD strictures, PTCS and biopsy findings revealed benign
strictures (Fig. 1). For those 27 patients, the mean values for
ALP, GGT and total bilirubin were 251 IU/L±221.6, 205
IU/L±198.5 and 3.2 mg/dL±4.96, respectively, and these
mean values were significantly lower than those of the malig-
nant distal CBD stricture group (p<0.05). For one patient,
radiology showed a benign stricture while PTCS and biopsy
findings showed a malignant stricture (Fig. 2).
Three of 95 patients experienced some complications in-
cluding deep sedation (n=1) and minor bleeding (n=2) dur-
ing cholangioscopy. They recovered following conservative
management and there was no other complication such as
pancreatitis or cholangitis. 
DISCUSSION
The present retrospective study showed that combined use
of PTCS-guided biopsy and tumor vessel observation result-
ed in a highly accurate method for diagnosing distal CBD
strictures. This approach was superior to the use of CT, MRCP
and direct cholangiography. These observations show that
PTCS would be useful in diagnosing distal CBD strictures
in cases that radiologic findings are ambiguous or ERCP
techniques are inadequate.
After the mid 1970’s, PTCS was predominantly perform-
ed in Asian countries such as Taiwan, Korea and Japan, where
there had been a high prevalence of intrahepatic stones and
cholangiocarcinomas (7, 8). The disadvantages of this proce-
dure are that it is invasive and requires sinus tract dilatation
which takes a relatively long time (9). However, the advan-
tages are direct visualization of the biliary mucosa and the
ability to perform a PTCS-guided biopsy (10, 11). 
The sensitivity of PTCS-guided biopsy was reported as
80-89% (12, 13), and the present study found it to be 85.7%.
The previous prospective studies reported that the sensitivi-
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Fig. 2. Studies of a 64-yr-old male patient. While radiologic findings suggested a benign stricture, PTCS imaging showed hyperemic mucosa
and tumor vessels, and PTCS-guided biopsy data revealed an adenocarcinoma. (A, B) CT image showing no wall thickening or enhance-
ment. (C) MRCP image showing gradual narrowing and symmetric narrowing. (D) Percutaneous transhepatic cholangiogram image show-
ing gradual narrowing and smooth narrowing. (E) PTCS image showing hyperemic mucosa and tumor vessels in the distal common bile
duct. 
A B C
D Ety of ERCP-guided biopsy and brush cytology was 61-75%
for biliary tumors (14, 15). In some cases of distal CBD stric-
ture, ERCP-guided biopsy is more technically difficult. Thus,
cholangioscopic biopsy appears to be very useful since a clin-
ician can precisely perform a targeted mucosal biopsy dur-
ing continuous observation. In the current study, the num-
ber of patients who underwent ERCP-guided biopsy and
brush cytology was so small that we could not compare ERCP
with PTCS in terms of tissue diagnosis.
Sato et al. has also reported that PTCS-guided biopsy can
detect invasive carcinomas only in the superficial layers of the
bile duct and diagnosis of intramural extension of invasive
carcinoma is difficult with PTCS even when the lesion is
biopsied (16). Therefore, reliable diagnostic criteria are requir-
ed for accurate differential diagnosis in cases of difficult biop-
sies. PTCS is a useful method for distinguishing cholangio-
carcinomas from other benign CBD strictures as it provides
direct visualization of any tumor vessels. In the bile duct
mucosa, the tumor vessel is an abnormal tortuous and ser-
pentine vascular structure at the circumference of the cancer
mucosa (17), and is important for tumor nutrition. Such a
vessel does not exist on a benign mucosal surface.
Of the 35 malignant group patients, biopsy results showed
chronic inflammation in 3 patients, and adequate biopsy
specimens could not be obtained in 2 patients. Five patients
could not initially be confidently placed in either the malig-
nant or benign group and the malignant distal CBD stric-
tures all were confirmed by surgical resection. Four of those
5 patients had tumor vessels and only tumor vessel was asso-
ciated with malignant distal CBD stricture on multivariate
analysis. Therefore, it appears that the presence of a tumor
vessel is a valuable clue for identifying malignancy. It is mean-
ingful that observation of a tumor vessel in distal CBD stric-
tures by PTCS because observation of a tumor vessel by ERCP
is impossible.
The present study documented PTCS-guided biopsy find-
ings combined with tumor vessel observation provided the
most precise preoperative diagnosis. This observation is con-
sistent with that of a previous study involving 41 malignant
biliary stricture patients that reported that the sensitivity of
tumor vessel observation was 61%, the sensitivity of PTCS-
guided biopsy findings was 80%, while the sensitivity of
the two methods combined were 96% (12).
In the present study, patients who failed ERCP due to
unsuccessful cannulation did not undergo peroral cholan-
gioscopy which would have been much less invasive. In addi-
tion, endoscopic ultrasound-guided fine-needle aspiration
(EUS-FNA) for the evaluation of distal CBD strictures was
not performed. 
The diagnostic utility of peroral cholangioscopy has not
yet been examined vigorously and the observation of far dis-
tal CBD on peroral cholangioscopy is techniqually difficult.
The fragility of the equipment and technical difficulties hold
back its popularity. 
EUS-FNA has been shown, in many series, to be highly
accurate for the diagnosis of pancreatic masses; sensitivity
rates for malignancy range from 60% to 93% (18-23). In a
prospective study, it has been demonstrated that the sensitivi-
ty of EUS-based techniques for the diagnosis of malignant
biliary stricture was only 25% and EUS-guided biopsy was
superior for pancreatic mass (14). In that study, if a mass lesion
was noted around the bile duct, EUS-FNA was attempted
and if a circumscribed mass was not demonstrated by EUS,
needle puncture was not attempted. There is few published
data in respect to EUS-guided tissue sampling of distal CBD
stricture without definite CBD mass on radiologic imaging.
EUS-FNA, therefore, may not be more valuable than PTCS
with biopsy for the evaluation of distal CBD stricture with-
out visible tumor in distal CBD. 
Guidelines need to be developed to determine which dis-
tal CBD stricture cases require PTCS. We suggest PTCS be
undertaken in patients in whom it is difficult to determine
whether the distal CBD strictures are benign or malignant
by radiological findings and ERCP and get ERCP-guided
tissue sampling are not feasible: Billroth type II surgery, can-
nulation failure, tight distal CBD strictures and etc. 
The present study was retrospective and therefore has the
limitations inherent in such a study design. In addition, the
number of patients who underwent all three imaging proce-
dures (CT, MRCP and direct cholangiography) was relative-
ly small, so analysis involved patients who had undergone at
least two of the three procedures. Furthermore, on the inter-
pretation of CT, MRCP and direct cholangiography findings
for distal CBD strictures, it is likely that observational dis-
agreement for the evaluation of the results exist. Therefore,
the evaluation of these imaging modalities by one radiolo-
gist may be biased. Moreover, sensitivity of CT may be under-
estimated because we did not adjust for the fact that, prior to
March 2001, evaluation of biliary tract disease was performed
by conventional abdomen CT, which was later replaced by
dynamic biliary CT. Thus, the outcomes of this study must
be considered in the context of these limitations. 
In conclusion, the present study found that due to its abil-
ity to provide direct visualization of the mucosa and any tumor
vessels, and to its ability to guide biopsies, PTCS was a use-
ful method for identifying malignant distal CBD strictures
compared to CT, MRCP and direct cholangiography. In par-
ticular, we recommend PTCS to obtain an accurate diagnoses
in cases where laboratory findings, radiographic findings and
tissue sampling results following ERCP are inconclusive to
exclude a malignant distal CBD stricture. 
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